Expertise in
5
conditions

Pinhua L. Pan

No.139 Renmin Middle Road, 
Changsha, CN 
Expertise in
5
conditions
No.139 Renmin Middle Road, 
Changsha, CN 
OverviewLocationsClinical Research

Overview

Pinhua Pan practices in Changsha, China. Pan is highly rated in 5 conditions, according to our data. Their top areas of expertise are Pneumonia, Acute Respiratory Distress Syndrome (ARDS), Chronic Obstructive Pulmonary Disease (COPD), and Sepsis.

Their clinical research consists of co-authoring 159 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

No.139 Renmin Middle Road, Changsha, 410011, China
Other Locations
No. 87 Xiangya Rd, Changsha, 410008, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
Enrollment Status: Completed
Publish Date: December 11, 2024
Intervention Type: Biological, Drug
Study Drug: Mepolizumab
Study Phase: Phase 3
Multicenter, Open-label, Phase II Study with a Safety Lead-in Part Investigating the Efficacy, Safety and Pharmacokinetics of Encorafenib and Binimetinib Combination in BRAF V600E Mutated Chinese Patients with Metastatic Non-Small Cell Lung Cancer Who Are BRAF- and MEK Inhibitor Treatment-naïve
Multicenter, Open-label, Phase II Study with a Safety Lead-in Part Investigating the Efficacy, Safety and Pharmacokinetics of Encorafenib and Binimetinib Combination in BRAF V600E Mutated Chinese Patients with Metastatic Non-Small Cell Lung Cancer Who Are BRAF- and MEK Inhibitor Treatment-naïve
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2024
Intervention Type: Drug
Study Drugs: Encorafenib, Binimetinib
Study Phase: Phase 2
View 1 Less Clinical Trial

159 Total Publications

GWAS study of myelosuppression among NSCLC patients receiving platinum-based combination chemotherapy.
GWAS study of myelosuppression among NSCLC patients receiving platinum-based combination chemotherapy.
Journal: Acta biochimica et biophysica Sinica
Published: April 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Pan's expertise for a condition
ConditionClose
      View All 28 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile